{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:24:39Z","timestamp":1782433479540,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004935","name":"S\u00fcleyman Demirel \u00dcniversitesi","doi-asserted-by":"publisher","award":["TSG-2020-8134"],"award-info":[{"award-number":["TSG-2020-8134"]}],"id":[{"id":"10.13039\/501100004935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02695-1","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T02:02:22Z","timestamp":1680573742000},"page":"2119-2128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of adalimumab on experimental corneal neovascularization model"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3523-8479","authenticated-orcid":false,"given":"Dilek","family":"\u00d6zkaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fah","family":"Usta Sofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehtap","family":"Savran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"\u00d6zg\u00f6\u00e7men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Ertu\u011frul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"2695_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","volume":"31","author":"T Al-Debasi","year":"2017","unstructured":"Al-Debasi T, Al-Bekairy A, Al-Katheri A et al (2017) Topical versus subconjunctival anti-vascular endothelial growth factor (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol 31:99\u2013105","journal-title":"Saudi J Ophthalmol"},{"key":"2695_CR2","first-page":"264","volume":"104","author":"DT Azar","year":"2006","unstructured":"Azar DT (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol 104:264\u2013302","journal-title":"Trans Am Ophthalmol"},{"key":"2695_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcdb.2007.08.014","volume":"19","author":"DC Beebe","year":"2008","unstructured":"Beebe DC (2008) Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin Cell Dev Biol 19:125\u2013133","journal-title":"Semin Cell Dev Biol"},{"key":"2695_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","volume":"43","author":"P Lee","year":"1998","unstructured":"Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: An epidemiologic review. Surv Ophthalmol 43:245\u2013269","journal-title":"Surv Ophthalmol"},{"key":"2695_CR5","first-page":"1625","volume":"37","author":"BM Kenyon","year":"1996","unstructured":"Kenyon BM, Voest EE, Chen CC et al (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol 37:1625\u20131632","journal-title":"Invest Ophthalmol"},{"key":"2695_CR6","first-page":"136","volume":"6","author":"EE Akar","year":"2016","unstructured":"Akar EE, Oner V, K\u00fc\u00e7\u00fckerd\u00f6nmez C et al (2016) Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model. Int J Ophthalmol 6:136\u2013140","journal-title":"Int J Ophthalmol"},{"key":"2695_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094205","volume":"9","author":"WL Chen","year":"2014","unstructured":"Chen WL, Chen YM, Chu HS et al (2014) Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization. PLoS ONE 9:e94205","journal-title":"PLoS ONE"},{"key":"2695_CR8","first-page":"588","volume":"6","author":"J Kim","year":"2013","unstructured":"Kim J, Kim D, Kim ES et al (2013) Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization. Int J Ophthalmol 6:588\u2013591","journal-title":"Int J Ophthalmol"},{"key":"2695_CR9","first-page":"1090","volume":"11","author":"B Ulas","year":"2018","unstructured":"Ulas B, Altan-Yaycioglu R, Bal N (2018) Comparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularization. Int J Ophthalmol 11:1090\u20131095","journal-title":"Int J Ophthalmol"},{"key":"2695_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","volume":"27","author":"TI Kim","year":"2009","unstructured":"Kim TI, Kim SW, Kim S et al (2009) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27:349\u2013352","journal-title":"Cornea"},{"key":"2695_CR11","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ et al (1997) Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593\u20134599","journal-title":"Cancer Res"},{"key":"2695_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/IAE.0b013e31804b3e15","volume":"27","author":"MV Emerson","year":"2007","unstructured":"Emerson MV, Lauer AK, Flaxel CJ et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439\u2013444","journal-title":"Retina"},{"key":"2695_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/157339909787314121","volume":"5","author":"JF Arevalo","year":"2009","unstructured":"Arevalo JF, Garcia-Amaris RA (2009) Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 5:39\u201346","journal-title":"Curr Diabetes Rev"},{"key":"2695_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","volume":"16","author":"D Roshandel","year":"2018","unstructured":"Roshandel D, Eslani M, Baradaran-Rafii A et al (2018) Current and emerging therapies for corneal neovascularization. Ocul Surf 16:398\u2013414","journal-title":"Ocul Surf"},{"key":"2695_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0962-8924(01)02064-5","volume":"9","author":"V Baud","year":"2001","unstructured":"Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 9:372\u2013377","journal-title":"Trends Cell Biol"},{"key":"2695_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1023\/A:1018377621102","volume":"1","author":"T Ueda","year":"1998","unstructured":"Ueda T, Ueda T, Fukuda S et al (1998) Lipid hydroperoxide-induced tumor necrosis factor (TNF)-alpha, vascular endothelial growth factor and neovascularization in the rabbit cornea: effect of TNF inhibition. Angiogenesis 1:174\u2013184","journal-title":"Angiogenesis"},{"key":"2695_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/ICL.0000000000000071","volume":"41","author":"G Ferrari","year":"2015","unstructured":"Ferrari G, Bignami F, Rama P (2015) Tumor necrosis factor-\u03b1 inhibitors as a treatment of corneal hemangiogenesis and lymphangiogenesis. Eye Contact Lens 41:72\u201376","journal-title":"Eye Contact Lens"},{"key":"2695_CR18","first-page":"1327","volume":"41","author":"RR Mohan","year":"2000","unstructured":"Mohan RR, Mohan RR, Kim WJ et al (2000) Modulation of TNF-alpha-induced apoptosis in corneal fibroblasts by transcription factor NF-kappaB. Invest Ophthalmol Vis Sci 41:1327\u20131336","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICO.0b013e31812f6d14","volume":"26","author":"S Saika","year":"2007","unstructured":"Saika S (2007) Yin and yang in cytokine regulation of corneal wound healing: Roles of TNF-alpha. Cornea 26:70\u201374","journal-title":"Cornea"},{"key":"2695_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/ICO.0000000000000071","volume":"33","author":"F Cade","year":"2014","unstructured":"Cade F, Paschalis EI, Regatieri CV et al (2014) Alkali burn to the eye: protection using TNFa inhibition. Cornea 33:382\u2013389","journal-title":"Cornea"},{"key":"2695_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1167\/iovs.12-10782","volume":"54","author":"G Ferrari","year":"2013","unstructured":"Ferrari G, Bignami F, Giacomini C et al (2013) Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci 54:1680\u20131688","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12348-014-0026-8","volume":"4","author":"I Pascual-Camps","year":"2014","unstructured":"Pascual-Camps I, Hern\u00e1ndez-Mart\u00ednez P, Monje-Fern\u00e1ndez L et al (2014) Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders. J Ophthalmic Inflamm Infect 4:26","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2695_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","volume":"135","author":"J Sheppard","year":"2017","unstructured":"Sheppard J, Joshi A, Betts KA et al (2017) Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol 135:511\u2013518","journal-title":"JAMA Ophthalmol"},{"key":"2695_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3109\/02713688508999984","volume":"4","author":"JM Mahoney","year":"1985","unstructured":"Mahoney JM, Waterbury LD (1985) Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 4:531\u2013535","journal-title":"Curr Eye Res"},{"key":"2695_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12301-011-0002-6","volume":"7","author":"A Refaiy","year":"2011","unstructured":"Refaiy A, Muhammad E, ElGanainy E (2011) Semiquantitative smoothelin expression in detection of muscle invasion in transurethral resection and cystectomy specimens in cases of urinary bladder carcinoma. Afr J Urol 7:6\u201310","journal-title":"Afr J Urol"},{"key":"2695_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0300985813485099","volume":"50","author":"KN Gibson-Corley","year":"2013","unstructured":"Gibson-Corley KN, Olivier AK, Meyerholz DK (2013) Principles for valid histopathologic scoring in research. Vet Pathol 50:1007\u20131015","journal-title":"Vet Pathol"},{"key":"2695_CR27","first-page":"182","volume":"8","author":"NS Abdelfattah","year":"2015","unstructured":"Abdelfattah NS, Amgad M, Zayed AA et al (2015) Clinical correlates of common corneal neovascular diseases: A literature review. Int J Ophthalmol 8:182\u2013193","journal-title":"Int J Ophthalmol"},{"issue":"Suppl","key":"2695_CR28","first-page":"593","volume":"37","author":"KA Colby","year":"1996","unstructured":"Colby KA, Adamis AP (1996) Prevalence of corneal neovascularization in a general eye service population (abstract). Invest Ophthalmol Vis Sci 37(Suppl):593","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR29","first-page":"18","volume":"39","author":"S Amano","year":"1998","unstructured":"Amano S, Rohan R, Kuroki M et al (1998) Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18\u201322","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Chen L, Borges LP et al (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113:1040\u20131050","journal-title":"J Clin Invest"},{"key":"2695_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.22336\/rjo.2019.4","volume":"63","author":"Z Sharif","year":"2019","unstructured":"Sharif Z, Sharif W (2019) Corneal neovascularization: updates on pathophysiology, investigations and management. Rom J Ophthalmol 63:15\u201322","journal-title":"Rom J Ophthalmol"},{"key":"2695_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2005.09.018","volume":"171","author":"M Hangai","year":"2006","unstructured":"Hangai M, He S, Hoffmann S et al (2006) Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol 171:45\u201356","journal-title":"J Neuroimmunol"},{"key":"2695_CR33","first-page":"4181","volume":"63","author":"LB Nabors","year":"2003","unstructured":"Nabors LB, Suswam E, Huang Y (2003) Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Canc Res 63:4181\u20134187","journal-title":"Canc Res"},{"key":"2695_CR34","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1167\/iovs.11-7912","volume":"52","author":"R Robinson","year":"2011","unstructured":"Robinson R, Ho CE, Tan QS et al (2011) Fluvastatin downregulates VEGF-A expression in TNF-\u03b1-induced retinal vessel tortuosity. Invest Ophthalmol Vis Sci 52:7423\u20137431","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1167\/iovs.16-20339","volume":"58","author":"C Zhou","year":"2017","unstructured":"Zhou C, Robert MC, Kapoulea V et al (2017) Sustained subconjunctival delivery of infliximab protects the cornea and retina following alkali burn to the eye. Invest Ophthalmol Vis Sci 58:96\u2013105","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2695_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/ICO.0b013e318271cc2a","volume":"32","author":"JW Kim","year":"2013","unstructured":"Kim JW, Chung SK (2013) The effect of topical infliximab on corneal neovascularization in rabbits. Cornea 32:185\u2013190","journal-title":"Cornea"},{"key":"2695_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcjo.2012.12.003","volume":"48","author":"O Ozdemir","year":"2013","unstructured":"Ozdemir O, Altintas O, Altintas L et al (2013) Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization. Can J Ophthalmol 48:115\u2013120","journal-title":"Can J Ophthalmol"},{"key":"2695_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5935\/0004-2749.20170061","volume":"80","author":"GJA Lopes","year":"2017","unstructured":"Lopes GJA, Casella AMB, Oguido AP et al (2017) Effects of topical and subconjunctival use of bevacizumab on corneal neovascularization in rabbits\u2019 eyes. Arq Bras Oftalmol 80:252\u2013256","journal-title":"Arq Bras Oftalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02695-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02695-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T07:23:04Z","timestamp":1684740184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02695-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02695-1","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}